Huons Launches 'Dreammel Sustained-Release Tablet' Containing Melatonin

Huons announced on August 12 that it has launched 'Dreammel Sustained-Release Tablet,' a pharmaceutical product whose main ingredient is melatonin.

Huons explained that, in light of the recent acceleration of population aging and the increasing prevalence of sleep disorders among the elderly, it is currently selling 'Zopista' (active ingredient: eszopiclone). With the launch of Dreammel Sustained-Release Tablet, the company has expanded its product lineup.

A Huons representative stated, "We expect that our new product, Dreammel Sustained-Release Tablet, will help create a healthier sleep environment for modern people," adding, "We will continue to do our utmost to manufacture and reliably supply high-quality pharmaceuticals."

Meanwhile, Huons is engaged in a wide range of healthcare businesses in line with its group philosophy of 'providing medical solutions for human health.' The company focuses on specialized pharmaceuticals such as local anesthetics and ophthalmic solutions, and also operates in beauty, wellness, and contract manufacturing (CMO) businesses.

This content was produced with the assistance of AI translation services.